Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer - Artios Pharma Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancer Study p...

#ArtiosPharma #ovariancancer #PlatinumResistantOvarianCancer #oncology #GynaecologicalOncology #ovariancancermonth #Alnodesertib #Gemcitabine #biopharma #DDRmedicines #highgradeserousovariancarcinoma #HGSOC #ATRinhibitor #platinumresistantHGSOC #DDRpathways #DNAreplicationstress
zurl.co/XtxxD